B of A Securities Upgrades BioCryst Pharma to Buy, Announces $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Tazeen Ahmad has upgraded BioCryst Pharma (NASDAQ:BCRX) from Neutral to Buy and announced a $10 price target.
July 13, 2023 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharma has been upgraded from Neutral to Buy by B of A Securities, with a new price target of $10.
The upgrade from Neutral to Buy by B of A Securities indicates a positive outlook for BioCryst Pharma. The new price target of $10 also suggests potential upside for the stock. This news is highly relevant and important for BCRX investors, and there is high confidence in this analysis based on the clear information provided in the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100